Fig. 6

Effect of TAT-TROY (234–371 aa) on the development of glioma. (a) U87 colonies incubated with TAT-TROY (234–371 aa) protein, or TAT (Control) were presented. (b) Quantification of U87 colonies. OD595 values of the group incubated with TAT-TROY (234–371 aa) protein are normalized to that of the control group. (c, d) TAT-TROY (234–371 aa) protein slowed U87 proliferation when FBS exposure. The proliferated cells were detected by BrdU staining (green). (e) The activation of NF-kB in U87 cells were attenuated after TAT-TROY (234–371 aa) treatment. (f) Subcutaneous glioma model mice induced by U87 cells (2 × 10⁶) were imaged by IVIS. GFP signal in nude mice bearing xenografted tumors were presented. Mice were treated with TAT-TROY (234–371 aa) (i.p., every 2 days, 2 mg/kg/injection). The group treated by TAT was the control. (g) Scatter diagram of individual tumor volume 21 days after implantation (n = 4 for each group). Each symbol represents a singl tumor. *P < 0.05